

US006020308A

United States Patent [19]

Dewhirst et al.

[11] **Patent Number:** 6,020,308

[45] **Date of Patent:** Feb. 1, 2000

[54] METHODS FOR IMPROVING THERAPEUTIC EFFECTIVENESS OF TREATMENT OF VASCULARIZATION DISORDERS

[75] Inventors: Mark W. Dewhirst, Chapel Hill; Robert E. Meyer, Cary; Joseph Bonaventura, Beaufort, all of N.C.; Joseph DeAngelo, Hamtramck, Mich.

[73] Assignees: Duke University, Durham; North Carolina State University, Raleigh; Apex Bioscience, Inc., Durham, all of N.C.

[21] Appl. No.: 09/126,930[22] Filed: Jul. 31, 1998

Related U.S. Application Data

[62] Division of application No. 08/709,938, Sep. 6, 1996, Pat. No. 5,788,958, which is a division of application No. 08/246,882, May 20, 1994, Pat. No. 5,554,638, which is a continuation-in-part of application No. 08/066,756, May 24, 1993, Pat. No. 5,612,310.

[56] References Cited

U.S. PATENT DOCUMENTS

4,001,401 1/1977 Bonsen et al. . 4,061,736 12/1977 Morris et al. . 4,301,144 11/1981 Iwashita. 4,321,259 3/1982 Nicolau. 4,377,512 3/1983 Ajisaka. 4,412,989 11/1983 Iwashita . 4,473,563 9/1984 Nicolau. 4,584,130 4/1986 Bucci et al. . 7/1986 Walder. 4,598,064 4,650,786 3/1987 Wong. 4,670,417 6/1987 Iwasaki . 4,710,488 12/1987 Wong. 4,812,449 3/1989 Rideout. 5,028,588 7/1991 Hoffman et al. . 5,266,594 11/1993 Dawson et al. . 5,273,875 12/1993 Griffith. 5,295,944 3/1994 Teicher et al. . 5,296,466 3/1994 Kilbourn et al. . 5,298,490 3/1994 Heavner et al. . 5,298,506 3/1994 Stamler et al. . 5,312,835 5/1994 Kilbourn et al. . 5.317.040 5/1994 Goldman. 5,334,380 8/1994 Kilbourn et al. .

FOREIGN PATENT DOCUMENTS

WO 88/03408 5/1988 WIPO . WO 90/13645 11/1990 WIPO . WO 93/08831 5/1993 WIPO .

OTHER PUBLICATIONS

Andrade et al., 1992, "Inhibitors of nitric oxide synthase selectively reduce flow in tumour—associated neovasculature", *Br. J. Pharmacol.* 107:1092–1095.

Babbs & DeWitt, 1981, "Physical Principles of local heat therapy for cancer", *Med. Instrum.* 15:367–373.

Botstein & Shortle, 1985, "Strategies and applications of in vitro mutagenesis", *Science* 229:1193–1201.

Brizel et al., 1994, Int. J. Radiation Oncol. Biol. Phys. 30:635-642.

Brown & Koong, 1991, "Therapeutic advantage of hypoxic cells in tumors: a theoretical study", *J. Natl. Cancer Inst.* 83:178–185

Caruthers et al., 1982, "New methods for synthesizing deoxyoligonucleotides", *Genetic Engineering*, Setlow & Hollaender eds., Plenum Press, NY, 4:1–17.

Chapman et al., 1987, "Keynote address: cellular reduction of nitroimidazole drugs: potential for selective chemotherapy and diagnosis of hypoxic cells", *Int. J. Rad. Oncol. Biol. Phys.* 16:911–917.

Chen et al., 1981, "Microvascular rarefaction in spontaneously hypertensive rat cremaster muscle", *Am. J. Physiol.* 241:H306–H310.

Collman et al., 1975, "Picket fence porphyrins.' Synthetic models for oxygen binding proteins", *J. Am. Chem. Soc.* 97:1427–1439.

W.A. Denny, 1995, "Bioreductive Drugs: A unique opportunity for de novo design", *Ninth Intl. Conf. on Chem. Modifier of Cancer Treatment*, abstr. p. 33.

De Venuto et al., 1979, "Appraisal of hemoglobin solution as a blood substitute", *Surgery Gynecol. and Obstetr.* 149:417–436.

Dewhirst et al., 1990, "The use of hydralazine to manipulate tumour temperatures during hyperthermia", *Int. J. Hyperthermia* 6:971–983.

Feola et al., 1983, "Development of a bovine stroma-free hemoglobin solution as a blood substitute", *Surgery Gynecol. and Obstetr.* 157:399–408.

Fishman et al., 1985, *Medicine* 2d Ed., J.B. Lippincott Co., Philadel., PA.

Froehler, 1986, "Synthesis of DNA via deoxynucleotide H–phosphonate intermediates", *Nucl. Acids Res.* 14:5399–5407.

Gatenby et al., 1988, "Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy", *Int. J. Radiation Oncology Biol. Phys.* 14:831–838.

Hahn & Shiu, 1985, "Protein synthesis, thermotolerance and step down heating", *Int. J. Radiat. Oncol. Biol. Phys.* 11:159–164.

Hilf et al., 1965, "Biochemical and morphologic properties of a new lactating mammary tumor line in the rat", *Cancer Res.* 25:286–299.

(List continued on next page.)

Primary Examiner—Michael P. Woodward
Assistant Examiner—Abdel A. Mohamed
Attorney, Agent, or Firm—Pennie & Edmonds LLP

[57] ABSTRACT

The present invention is directed to the use of an inhibitor of NO activity, such as a nitric oxide scavenger or an NO synthase inhibitor, as as an adjunct to treatment of inappropriate tissue vascularization disorders.

8 Claims, 14 Drawing Sheets